<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03121547</url>
  </required_header>
  <id_info>
    <org_study_id>131</org_study_id>
    <nct_id>NCT03121547</nct_id>
  </id_info>
  <brief_title>Opioid Induced Gait Variability</brief_title>
  <official_title>Opioid Induced Gait Variability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frederiksberg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Frederiksberg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      While the analgesic effects of opioids are well known, evidence suggest that there are&#xD;
      differences in the adverse dizziness of the different opioid types, which may influence the&#xD;
      gait function differently. However, this has not been investigated scientifically under&#xD;
      controlled conditions. Normal gait function is characterized by cyclic movements with a high&#xD;
      degree of predictability. As such, the amount of kinematic variability can provide important&#xD;
      information about a condition or an intervention that may affect the gait function .&#xD;
      Three-dimensional gait analysis is a recognized method to assess changes in stride-to-stride&#xD;
      variability associated with a medical condition or caused by an intervention. Thus, opioid&#xD;
      induced changes in gait variability, and possible differences between opioid types, can be&#xD;
      assessed objectively from differences in the variability of movements obtained from a&#xD;
      three-dimensional gait analysis.&#xD;
&#xD;
      The purpose of this study is to investigate differences in gait variability induced by two&#xD;
      different single-dose opioid formulations and an inert placebo in healthy volunteers and knee&#xD;
      osteoarthritis patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed as an experimental single center, double-blind treatment, cross-over&#xD;
      study with inert placebo, Tapentadol (Palexia Depot), and Tramadolhydrochlorid (Mandolgin&#xD;
      Retard), with a minimum of 7days wash-out periods.&#xD;
&#xD;
      At day 1 (Visit 1), baseline measurements are carried out before tablet administration.&#xD;
      Immediately after baseline measurements one tablet is administered, and hourly measurements&#xD;
      are performed for 6 hours. Subsequently all participants enter a minimum 7 day washout&#xD;
      period, after which they return to the facility to repeat the procedures at Visit 2 (day 8+)&#xD;
      and Visit 3 (day 15+). The order of treatments will be randomized (1:1:1).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 19, 2015</start_date>
  <completion_date type="Actual">January 29, 2016</completion_date>
  <primary_completion_date type="Actual">January 29, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Gait variability</measure>
    <time_frame>every hour from pre-tablet administration (hour 0) to hour 6</time_frame>
    <description>Three dimensional gait analysis during 6 minutes of continuous treadmill walking.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self reported dizziness</measure>
    <time_frame>every hour from pre-tablet administration (hour 0) to hour 6</time_frame>
    <description>Current dizziness is assessed by means of a 100 mm visual analog scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self reported knee pain</measure>
    <time_frame>every hour from pre-tablet administration (hour 0) to hour 6</time_frame>
    <description>Current knee pain is assessed by means of a 100 mm visual analog scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Opioid Induced Motor Disturbances</condition>
  <arm_group>
    <arm_group_label>Placebo oral tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One inert calcium tablet is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tramadol Hydrochloride 100 mg Extended Release Oral Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet containing 100 milligrams (mg) Mandolgin Retard, Sandoz is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tapentadol 50 mg Oral Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet containing 50 milligrams (mg) Palexia Depot, Grünenthal is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tapentadol 50 mg Oral Tablet</intervention_name>
    <description>1 tablet administered</description>
    <arm_group_label>Tapentadol 50 mg Oral Tablet</arm_group_label>
    <other_name>Palexia Depot (50 mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol Hydrochloride 100 mg Extended Release Oral Tablet</intervention_name>
    <description>1 tablet administered</description>
    <arm_group_label>Tramadol Hydrochloride 100 mg Extended Release Oral Tablet</arm_group_label>
    <other_name>Mandolgin Retard (100 mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>calcium tablet</description>
    <arm_group_label>Placebo oral tablet</arm_group_label>
    <other_name>Calcium tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy subjects:&#xD;
&#xD;
          -  In general good health, in the opinion of the Investigator, based on medical history&#xD;
             and physical examination.&#xD;
&#xD;
          -  Ability to comprehend and a willingness to provide written informed consent&#xD;
&#xD;
          -  Age between 50 and 75 years&#xD;
&#xD;
          -  No opioid usage 3 months prior to the study&#xD;
&#xD;
          -  No musculoskeletal pain requiring medical attention during the previous 3 months&#xD;
&#xD;
          -  Willing and able to complete study visits and procedures&#xD;
&#xD;
          -  Willing to hold activity, exercise level, and concurrent treatments/therapies&#xD;
             generally consistent during the study&#xD;
&#xD;
          -  A body mass index (BMI) of ≤30&#xD;
&#xD;
        Patients with knee osteoarthritis (OA)&#xD;
&#xD;
          -  Diagnosis of knee OA&#xD;
&#xD;
          -  Ability to comprehend and a willingness to provide written informed consent&#xD;
&#xD;
          -  Age between 50 and 75 years&#xD;
&#xD;
          -  No opioid usage 3 months prior to the study&#xD;
&#xD;
          -  Knee pain of at least 40 mm on a 0-100 mm visual analog scale (without analgesics)&#xD;
             representing the average pain intensity during the previous week&#xD;
&#xD;
          -  Willing to discontinue all pain medications 24 hours before and during examination&#xD;
             visits&#xD;
&#xD;
          -  Willing and able to complete study visits and procedures&#xD;
&#xD;
          -  Willing to hold activity, exercise level, and concurrent treatments/therapies&#xD;
             generally consistent during the study&#xD;
&#xD;
          -  In general good health, in the opinion of the Investigator, based on medical history&#xD;
             and physical examination.&#xD;
&#xD;
          -  A body mass index (BMI) of ≤30&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The same exclusion criteria apply for both healthy subjects and patients with knee&#xD;
        osteoarthritis:&#xD;
&#xD;
          -  Clinical signs of gait ataxia assessed by clinical neurological examination&#xD;
&#xD;
          -  Independent or unsteady walking (i.e. dependence on walking device or stumbling gait)&#xD;
&#xD;
          -  Counter indications to either of the investigational products, including but not&#xD;
             restricted to:&#xD;
&#xD;
               -  Allergy towards one or more of the investigational products or their&#xD;
                  excipient(s).&#xD;
&#xD;
               -  Significant respiratory depression&#xD;
&#xD;
               -  Current or serious asthma&#xD;
&#xD;
               -  Hypercapnia&#xD;
&#xD;
               -  Suspected or diagnosed paralytic ileus&#xD;
&#xD;
               -  Acute intoxication by alcohol, hypnotica, centrally acting analgesics,&#xD;
                  psychopharmaca or other pharmaceuticals.&#xD;
&#xD;
               -  Renal dysfunction&#xD;
&#xD;
               -  Hepatic dysfunction&#xD;
&#xD;
               -  Diseases of the biliary tract&#xD;
&#xD;
               -  Acute pancreatitis&#xD;
&#xD;
               -  Usage of monoamine oxidase inhibitors within the last 14 days&#xD;
&#xD;
               -  Galactose intolerance&#xD;
&#xD;
               -  Lactase deficiency&#xD;
&#xD;
               -  Glucose/galactose malabsorption&#xD;
&#xD;
               -  Epilepsy&#xD;
&#xD;
          -  Previous usage of opioids without pain reliving effect.&#xD;
&#xD;
          -  Patients who have a documented history of an allergic reaction or a clinically&#xD;
             significant intolerance to opioids&#xD;
&#xD;
          -  Malignant pain&#xD;
&#xD;
          -  Excessive joint laxity in the lower extremities indicative of functional ligamentous&#xD;
             deficiency.&#xD;
&#xD;
          -  Dependency of walking aid (stick, cane, roller etc.).&#xD;
&#xD;
          -  Positive Clock Drawing Test&#xD;
&#xD;
          -  Abuse of alcohol, medicine and narcotics within past 5 years.&#xD;
&#xD;
          -  History of symptoms of autoimmune disorders&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  History, diagnosis, or signs and symptoms of clinically significant neurological&#xD;
             disease&#xD;
&#xD;
          -  History, diagnosis, signs or symptoms of any clinically significant psychiatric&#xD;
             disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Bliddal, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Parker Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Parker Institute, Frederiksberg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2017</study_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Frederiksberg University Hospital</investigator_affiliation>
    <investigator_full_name>Henning Bliddal</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Tapentadol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

